

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

November 28, 2025

To

BSE Limited

Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company, at their meeting held on even date, i.e. November 28, 2025, have approved a capital expenditure of Rs. 189 Crs. for setting up a Research & Development (R&D) Center at the Company's leased premises at Genome Valley, Plot No. 15B, Phase-I, MN Park, Shamirpet, Turkapally, Hyderabad, Telangana. The requisite details are as under:

a) Existing Capacity	NA
b) Existing Capacity Utilization	NA
c) Proposed Capacity Addition	NA
d) Period within which the proposed capacity is to be added	NA
e) Investment required	Rs. 189 crores
f) Mode of financing	Through borrowings and Internal accruals
g) Rationale	Relocating the existing R&D center (approx. 0.45 lakh sq.ft.) by setting up a new state-of-the-art R&D center in a built-up area of about 1.35 lakh sq. ft.

This is for your information and records.

Yours sincerely,

For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary